First therapeutic intervention study in pre-symptomatic ALS, designed in collaboration with Biogen.

Oral presentation at AAN annual meeting: “Design of a Phase 3, Randomized, Placebo-Controlled Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Mutation Carriers: The ATLAS Study”